Indonesia is midway through a health system transformation organised around six pillars: primary care, referral services, health resilience, health financing, health workforce and health technology. The legal foundation is Health Law No. 17 of 2023, the Health Omnibus Law, which replaced eleven previous statutes. Government Regulation 28 of 2024 and Ministerial Regulation 5 of 2026 form the implementing chain, the latter consolidating and replacing forty prior ministerial regulations spanning five decades. The direction is consistent: shift from treatment to prevention, streamline licensing, admit qualified foreign medical practitioners under defined conditions, ease device and pharmaceutical market entry, and reduce dependence on imported inputs.
Key government and institutional actors include:
At 31 December 2025 the JKN scheme covered 282.7 million participants, 98.6 per cent of the population, having reached effective universal coverage in roughly a decade. The contracted network exceeds 23,000 primary care facilities and 3,100 referral hospitals; more than 66 per cent of partner hospitals are privately owned, and the number of contracted hospitals rose 88 per cent between 2014 and 2024. No other health system in the region provides a single payer relationship with a population of this size.
The binding constraint is workforce. Indonesia has roughly seven doctors per 10,000 people, below Thailand and the Philippines and far below Australia. Any intervention that raises clinical productivity, extends specialist reach beyond the major cities, or substitutes for scarce workforce capacity has an addressable need here that exists nowhere else in ASEAN at comparable scale. This is the reason digital health, diagnostics, task-shifting models and remote specialist services carry more strategic weight in Indonesia than elsewhere in the region.
Cek Kesehatan Gratis, the free national health check programme, is the largest preventive health undertaking in Indonesia's history. It reached 70 million people during 2025 and passed 82 million during 2026 by late August, against a target of 130 million for the year - roughly 46 per cent of the population. Screening is recorded through SATUSEHAT, so results flow into the individual's longitudinal health record and are accessible through the SATUSEHAT mobile application. From August 2026 the Ministry of Health began monitoring follow-up management data from at least 5,300 community health centres ahead of national expansion, with medication for hypertension, diabetes and cholesterol provided free for an initial period before transition to the national insurance scheme.
The clinical yield explains why the programme matters well beyond service delivery. Among 9.2 million participants re-screened in 2026 who had been recorded as healthy the previous year, approximately one million new cases of hypertension were identified; among 8.3 million re-examined for diabetes, 188,000 were newly diagnosed. A school-based strand screened more than 8.8 million students between January and July 2026. Repeated annually and written to a national data platform, this becomes a longitudinal population health dataset at a scale very few health systems anywhere can generate - and the single most valuable asset in the ecosystem for anyone working on early detection, chronic disease management or preventive health.
SATUSEHAT is Indonesia's national health information exchange, launched in 2022 as the delivery vehicle for the health technology pillar. It connects hospitals, clinics, laboratories, pharmacies, regulators, payers and digital service providers into a single interoperability layer, with associated modules for health workforce data and logistics, and is the standard to which health applications operating in Indonesia are expected to conform.
The Biomedical and Genome Science Initiative (BGSi) is the national genomics programme, operating a hub-and-spoke network anchored on Ministry of Health vertical hospitals, with samples processed centrally at BB Binomika and results designed to interoperate with SATUSEHAT. More than 10,000 whole genome sequences have been completed, alongside population-level pharmacogenomics analysis and the GENERASI SEHAT population cohort. Priority disease areas include cancers of the breast, lung, colon and cervix, tuberculosis, stroke and neurodegenerative disease, diabetes and metabolic disease, Duchenne muscular dystrophy and pulmonary arterial hypertension.
Indonesia's population genetics are among the most diverse on earth and among the least represented in global genomic reference data. That gap is a scientific opportunity for international research partnerships and, handled properly, a sovereign asset for Indonesia.
BGSi clinical hubs include:
Indonesia's research capacity is concentrated in a small number of large public universities with attached academic medical centres, now joined by international campuses established under the special economic zone framework.
Indonesia imports the overwhelming majority of its active pharmaceutical ingredients, and policy is explicitly directed at domestic substitution through local content requirements, fiscal incentives and a phased halal certification regime for medical devices, with Class A devices required to comply by October 2026, Class B by 2029 and Class C by 2034. For international manufacturers this makes partnership structure - local production, joint venture, technology transfer - the determining commercial variable rather than product quality alone. Foreign ownership rules have been progressively liberalised, and foreign investment hospitals may now diversify into clinics, laboratories, wellness centres and stem cell banks under a single operating entity.
Indonesia's most significant global health industrial asset is Bio Farma, the state-owned vaccine manufacturer and parent of the national pharmaceutical holding. Ranked ninth in the World Health Organization's 2023 global vaccine market report and the fifth-largest supplier through WHO channels, it distributes to more than 160 countries, holds twelve WHO-prequalified products and has annual capacity of around 3.1 billion doses, roughly half of which is exported. It is the only vaccine manufacturer in ASEAN holding WHO prequalification for export, supplies UNICEF and the Pan American Health Organization, has served as the Organisation of Islamic Cooperation Centre of Excellence for vaccines and biotechnology since 2018, and is establishing mRNA and viral vector rapid-response capability under a ten-year partnership with CEPI. For European and North American partners it is the most direct route into vaccine and biologics manufacturing collaboration anywhere in Southeast Asia.
Indonesia is the only country in ASEAN using special economic zone designation systematically to build health capacity, and the policy intent is explicit: convert outbound patient flow into domestic capability. More than two million Indonesians travel abroad for treatment each year, principally to Singapore and Malaysia. Three health-designated zones are now operating.
Zone status carries relaxations of direct relevance to international operators, including importation of medicines and devices not yet registered domestically, use of international naming conventions and exemptions from certain accreditation requirements.
Indonesia is the largest economy in ASEAN and the single most important source market for medical travel to both Malaysia and Singapore. The policy direction is unambiguous - bring that capacity onshore - and the instruments to do it are now in place. For European and North American partners this makes Indonesia a build market rather than an export market: the value sits in joint ventures, technology transfer, clinical training, research partnership and local manufacture, not in shipping finished products.
Read together with Singapore and Malaysia, Indonesia completes a corridor rather than adding a market. Singapore supplies research intensity, regulatory alignment and capital; Malaysia supplies manufacturing depth and clinical volume; Indonesia supplies population scale, genomic diversity and the region's largest unmet delivery need. Global Health Connector APAC works across all three.
